IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
• Year: 2000
Takeda cre ated a sec tion on its web site for the sub mis sion of li cens ing pro pos als from for eign bio tech nol -
ogy firms and re search sci en tists lack ing the re sources to de velop their own prod ucts or tech nol o gies.
Takeda will form re search al li ances and/or mar ket ing part ner ships for those sug ges tions deemed ap pro -
pri ate. It be came the first Jap a nese phar ma ceu ti cal firms to seek such partnerships through the Internet.
Six bulk vi ta min man u fac tur ers in clud ing Takeda set tled US le gal ac tions aris ing out of global price-fix ing
in the vi ta min mar ket, for up to $325 mil lion. Takeda will pay a max i mum of $27.3 mil lion, to be re corded
as a spe cial charge against its mid-year earn ings re sults for the year to March 31 2001. Daiichi, Eisai,
Aventis, BASF and Roche were the other com pa nies in volved in the set tle ment. The EU is also in ves ti gat -
ing a car tel, and ap proached 13 companies in July 2000.
Takeda and Mitsui Chem i cals (Ja pan) agreed to es tab lish a joint ven ture (Mitsui Takeda Chem i cals) in Ja -
pan that will merge the com pa nies’ ure thane and com pos ite ma te ri als busi nesses. This will en able
Takeda to di vest this busi ness as a move to wards fo cus ing on its core phar ma ceu ti cal area. Sub ject to
reg u la tory ap proval, the new busi ness was sched uled to be gin op er a tions in 2001. Af ter five years, Mitsui
will acquire Takeda’s 49% share.
Lilly and Takeda an nounced an un re stricted ed u ca tional grant to the US Na tional Di a be tes Ed u ca tion Ini -
tia tive. The funds will be used for the de vel op ment of pro grams for the man age ment of Type 2 diabetes.
A group of 43 Jap a nese phar ma ceu ti cal firms, in clud ing Takeda, formed a group to con duct re search on
sin gle nu cle o tide polymorphisms.
Takeda and BASF an nounced plans to com bine their bulk vi ta mins busi nesses. The com bined op er a tion
will have ap prox i mately 30% of the global vi ta mins mar ket. In Ja pan, a jv will be cre ated, owned 34% by
Takeda. Takeda’s vi ta min sub sid iar ies in the US, Can ada, Ger many and Sin ga pore will be trans ferred to
BASF. Out side Ja pan, BASF will as sume sole re spon si bil ity for the world wide mar ket ing of the com bined
vi ta min prod uct range. Takeda’s man u fac tur ing tech nol ogy and pat ents will be trans ferred to BASF, but
Takeda’s Vi ta mins and Food Com pany will con tinue to pro duce bulk vitamins, for exclusive supply to
BASF.
Takeda an nounced plans to ter mi nate its poly ure thane jv agree ment with BASF. Takeda’s 50% share of
Takeda Badisches Ure thanes In dus tries (TBU) was trans ferred to BASF Ja pan. Takeda ex plained that the
busi ness per for mance of TBU had been dis ap point ing, so it de cided to dis con tinue its investment.
Takeda’s new pro duc tion fa cil ity in Ire land went on line. The com pany spent Yen4 bil lion on the fa cil ity,
which has an out put ca pac ity of 750,000 tons per an num, and pro duces lansoprazole, mostly for the US
mar ket. The plant will also produce Actos.
Takeda an nounced the merger of its wholly owned US sub sid iar ies, Takeda Pharmaceuticals Amer ica
(TPA) and Takeda Amer ica Re search & De vel op ment. The lat ter’s func tions were trans ferred to TPA, for -
merly only re spon si ble for sales and mar ket ing, as of De cem ber 31 2000. Takeda hoped the strength -
ened link be tween its US mar ket ing and R&D op er a tions would max i mize the potential of every product.
The Bar ce lona Pro vin cial Court ruled that Boral Quimica SA (Spain) must re frain from man u fac tur ing or
mar ket ing lansoprazole, due to in fringe ment of Takeda’s Span ish pat ent. The rul ing set tled a case be gun
by Takeda in 1994; it re ceived a pos i tive ver dict in 1997, but Boral ap pealed. This ap peal has now been
dismissed.
TAP Hold ings changed its name to TAP Phar ma ceu ti cal Prod ucts.
© 2009 IMS Health In cor po rated or its af fil i ates Page 117